Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 146 ALL: Blinatumomab added to prephase and consolidation therapy in adult precursor B-ALL
2024-511050-44-00Phase 2Completed
- Sponsor
- HOVON
- Start
- Nov 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL), sponsored by HOVON. Primary endpoint: MRD-negative response after first blinatumomab consolidation. Started Nov 2024; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on 2024-511050-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511050-44-00.